All News

2019

May

Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Read More
Featured News / May 15, 2019

SOLAR-1 NEJM Publication

Read More
Media Release / May 10, 2019

Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

Read More
Vice President and Head of US Hematology at Novartis shares her story for “Novartis Presents: Women in Science.”
Story / May 09, 2019

Women in Science: Sandrine Piret-Gérard

Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.

Read More
Media Release / May 09, 2019

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

Read More
Media Release / May 09, 2019

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Read More
Media Release / May 08, 2019

Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

Read More
Media Release / May 07, 2019

New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

Read More
Media Release / May 07, 2019

Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS

Read More
Media Release / May 05, 2019

AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More